Physician profile
Joshua E Bostick
NPI 1184937690
$6,216.85
in general payments reported to CMS, 2019-2025
17 companies · $558 in 2025
The $558 reported for 2025 was more than what 80% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,042 · 2020: $358 · 2021: $715 · 2022: $1,264 · 2023: $1,322 · 2024: $958 · 2025: $558.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,714 · Entertainment: $124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,713.66 |
| Entertainment | $124.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $1,403.41 | 2022-2025 | Infuse, Vyzulta, Miebo |
| Johnson & Johnson Vision Care, INC. | $1,366.50 | 2019-2025 | Acuvue |
| Alcon Vision LLC | $1,179.39 | 2019-2025 | Total30, Lensx, Precision7 |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $919.09 | 2019-2021 | |
| Coopervision INC. | $248.83 | 2019-2024 | Myday Contact Lens |
| Sun Pharmaceutical Industries INC. | $216.90 | 2021-2023 | Cequa |
| Allergan, INC. | $182.60 | 2019-2021 | |
| Oyster Point Pharma, INC. | $158.74 | 2022-2025 | Tyrvaya, Ryzumvi |
| Optos, INC. | $124.44 | 2024 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Rxsight INC | $105.16 | 2023 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Abbvie INC. | $78.24 | 2022-2023 | Lumigan, Alphagan P, Vuity |
| Maculogix, INC. | $77.42 | 2019 | |
| Mallinckrodt Hospital Products INC. | $55.36 | 2022-2023 | Acthar |
| Eyevance Pharmaceuticals LLC | $34.08 | 2022 | |
| Carl Zeiss Meditec USA, INC. | $27.88 | 2023 | Cirrus Hd-Oct |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $22.95 | 2024 | Xdemvy |
| Biotissue Holdings INC. | $15.86 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joshua Bostick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.